David L. Becton
Researcher
Also affiliated: Children's Oncology Group (2004); Cincinnati Children's Hospital Medical Center (2008); American Cancer Society (1986); Monroe Carell Jr. Children's Hospital (2005); Arkansas Children's Hospital (1987–2025); St. Jude Children's Research Hospital (2002–2008); Lucile Packard Children's Hospital (2008); Duke University (1985–1996); Wayne State University (2005); University of Washington (2004); University of Arkansas Medical Center (2001–2018); Massachusetts General Hospital (2004–2005); Fred Hutch Cancer Center (2004); Novem (Netherlands) (1997); The Barbara Ann Karmanos Cancer Institute (2005); Arkansas Cardiology (2002); Arcadia (2004–2005); Duke Medical Center (1984–1987); Children's Hospital of Michigan (1999–2008); Children's Oncology Group (2004–2008); Children's Healthcare of Atlanta (2008); Duke University Hospital (1985–1987); Sidney Kimmel Comprehensive Cancer Center (2005); Virginia Commonwealth University Medical Center (2005); Texas Tech University Health Sciences Center (2024); Stanford University (2001–2005); Amarillo College (2024)
Faculty Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
David L. Becton studies child and adolescent health, with a focus on pediatric oncology and infectious diseases. His work has investigated clinical features and risk factors associated with multisystem inflammatory syndrome in children, particularly in the context of COVID-19 and cancer. He has also explored the genetic underpinnings of certain pediatric leukemias, examining how epigenetic factors influence treatment resistance.
Becton's research extends to specific challenges in pediatric oncology, including intracranial hypotension following lumbar puncture and the presentation of rare genetic syndromes like Noonan Syndrome in infants. He has also published on the genetic aspects of Li-Fraumeni syndrome in twins, highlighting divergent cancer timelines despite shared genetics. His scholarship metrics include an h-index of 28, with 90 total publications and 2,959 citations, and he is designated as a highly cited researcher.
His collaborations at the University of Arkansas for Medical Sciences include work with P Strebeck, Jason E. Farrar, Lauren Banko, and Megan S. Evans, with whom he has co-authored multiple publications. Becton also leads a research group and has recently been active in research, with publications extending to 2025.
Metrics
- h-index: 28
- Publications: 90
- Citations: 2,966
Selected Publications
-
Severe transient abnormal myelopoiesis in a premature neonate with Trisomy 21: a rare, fatal presentation with complex therapeutic challenges (2026)
-
Intracranial Hypotension in Pediatric Oncology Patients Following Lumbar Puncture: A Case Series (2025)
-
Violaceous Nodules in an Infant With Noonan Syndrome: Challenge (2025)
-
Violaceous Nodules in an Infant With Noonan Syndrome: Answer (2025)
-
Anemia as a presenting sign for gastrinoma (2024)
-
Infection masking leukemia (2024)
-
Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital (2021)
-
Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography (2020)
-
Short‐term side effects and patient‐reported outcomes of bleomycin sclerotherapy in vascular malformations (2018)
-
Nutlin‐3 treatment spares cisplatin‐induced inhibition of bone healing while maintaining osteosarcoma toxicity (2016)
-
Cisplatin inhibits bone healing during distraction osteogenesis (2013)
-
Cardiac Myeloid Sarcoma (2011)
-
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML (2010)
-
Index of Suspicion (2009)
-
C-Reactive Protein and Soluble IL-2Receptor Correlate with High Risk of Clinical Sepsis Among Children with Fever and Neutropenia. (2009)
Grants & Funding
As listed on this researcher's institutional profile.
- Prevention of Complications of Hemophilia Centers for Disease Control & Prevention
- PROPHYLACTIC PENICILLIN IN SICKLE CELL DISEASE NIH/NHLBI
- PEDIATRIC ONCOLOGY GROUP NIH
Collaboration Network
Top Collaborators
- Anemia as a presenting sign for gastrinoma
- Violaceous Nodules in an Infant With Noonan Syndrome: Answer
- Violaceous Nodules in an Infant With Noonan Syndrome: Challenge
- Violaceous Nodules in an Infant With Noonan Syndrome: Answer
- Violaceous Nodules in an Infant With Noonan Syndrome: Challenge
- Violaceous Nodules in an Infant With Noonan Syndrome: Answer
- Violaceous Nodules in an Infant With Noonan Syndrome: Challenge
- Violaceous Nodules in an Infant With Noonan Syndrome: Answer
- Violaceous Nodules in an Infant With Noonan Syndrome: Challenge
- Violaceous Nodules in an Infant With Noonan Syndrome: Answer
- Violaceous Nodules in an Infant With Noonan Syndrome: Challenge
- Violaceous Nodules in an Infant With Noonan Syndrome: Answer
- Violaceous Nodules in an Infant With Noonan Syndrome: Challenge
- Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital
- Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital
- Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital
- Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital
- Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital
- Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital
- Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital
- Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital
- Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital
Similar Researchers
Based on overlapping research topics